At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Linsitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Linsitinib, and 1 other intervention for Carney Complex and 3 related conditions. Completed, enrolled 20 participants across 8 sites.
Detailed Summary
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedMar 2012
Primary CompletionOct 2015
TodayJul 2026
First PostedMar 22, 2012
Enrollment StartMar 1, 2012
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.3 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Linsitinibdrug
Given PO
Pharmacological Studyother
Correlative studies